NEW YORK (GenomeWeb News) – Berg Pharma will use its Integrative Biology platform to identify drug targets and biomarkers in clinical samples from the Parkinson's Institute of Sunnyvale, Calif., under a partnership announced today.

The Berg platform is used to compare and study normal and disease signatures by integrating a range of data sets, including genomic, metabolomic, proteomic, and lipidomic data. Under the partnership, Berg Pharma will have access to clinically annotated tissue samples representing various types of Parkinson's disease and specific mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: methylation patterns in multiple myeloma, recent Y chromosome bottleneck, and more.

By studying the spectra of microbes on Earth, a team of researchers hopes to be better equipped to detect any on other worlds.

SolveBio's Mark Kaganovich says at TechCrunch that genomics needs an app to push it into the mainstream.

A University of Michigan team is using a Facebook app to recruit and keep in touch with participants in its 'Genes for Good' project.